This post was written by Melanie Riehl Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor Monlunabant ...
Some results have been hidden because they may be inaccessible to you